RMC-6236 (Unresectable or Metastatic Colorectal Cancer or Pancreatic Cancer)

Purpose of this Study

We are doing this study to see if an experimental drug called RMC-6236 (the study drug) is a safe and effective option for treating colorectal or pancreatic cancer when it is combined with different chemotherapy drugs.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with metastatic or unresectable colorectal cancer; OR
  • Are diagnosed with metastatic pancreatic cancer
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

What is Involved?

Description

If you choose to join this study, you will:
  • Receive the study drug and chemotherapy with or without irinotecan, or with bevacizumab
  • Have a tumor biopsy done, if necessary
  • Have blood draws
  • Have imaging scans (CT or MRI)

Study Details

Full Title

Study of RMC-6236 in Combination with 5-flourouracil-based Regimens in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma– Subprotocol A

Principal Investigator

John
Strickler

Protocol Number

PRO00115657

NCT ID

NCT06445062

Phase

I/II

Enrollment Status

Open to Enrollment
ClinicalTrials.gov